Last reviewed 2026-04-22 · How we verify

Carvedilol Phosphate modified release formulation

Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.

Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction post-myocardial infarction.

At a glance

Mechanism of action

Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. The modified-release formulation provides sustained drug delivery over 24 hours, allowing once-daily dosing. This formulation maintains the pharmacological effects of standard carvedilol while improving patient compliance.

Approved indications

• Hypertension
• Heart failure with reduced ejection fraction
• Left ventricular dysfunction post-myocardial infarction
• Angina pectoris

Common side effects

• Dizziness
• Fatigue
• Bradycardia
• Hypotension
• Hyperglycemia
• Erectile dysfunction

Key clinical trials

• COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension (PHASE3)
• COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.